This was a generally well-conducted meta-analysis exploring the risk of thrombocytopenia in patients prescribed lowmolecular-weight heparin or unfractionated heparin for venous thromboembolism. The authors performed a thorough quality assessment of the included studies and used appropriate statistical methods to combine the data. The conclusions seem reliable based on the evidence presented.
Authors' objectives
To compare the incidence of thrombocytopenia between low molecular weight heparin (LMWH) and unfractionated heparin (UFH) during treatment of pulmonary embolism (PE) and/or deep vein thrombosis (DVT).
Searching
Trials in English were identified through a computerised bibliographic search of MEDLINE, from January 1985 to June 2006; the search terms were reported. The references of retrieved reviews and meta-analyses were checked for additional studies, and publishers of included articles were contacted in an attempt to identify unpublished trials.
Study selection Study designs of evaluations included in the review
Randomised controlled trials (RCTs) were eligible for inclusion.
Specific interventions included in the review
Studies comparing LMWH with UFH of any type, preparation and route of administration for venous thromboembolism were eligible for inclusion if the planned follow-up was the same for LMWH and UFH. The specific thrombolytic drug therapies and doses were reported in the paper. All LMWH therapies were delivered subcutaneously, apart from one trial in which intravenous administration was used in addition to subcutaneous delivery.
Participants included in the review
Studies in patients with objectively diagnosed PE or DVT were eligible for inclusion. Objective diagnosis included pulmonary angiography, contrast venography, duplex ultrasound, Doppler scan, ventilation-perfusion scan, and/or computed tomographic scanning.
Outcomes assessed in the review
Studies that reported heparin-induced thrombocytopenia and heparin-induced thrombocytopenia with thrombosis were eligible for inclusion. Studies were required to define thrombocytopenia objectively, screen and measure platelet counts, and compare rates of thrombocytopenia for LMWH with UFH in the initial treatment of PE or DVT. For the primary analyses, 'thrombocytopenia' during LMWH or UFH therapy was defined as the occurrence of platelet counts in the range of 80,000 to 120,000/microL, or a decrease of at least 50% from a previously measured platelet level. A secondary analysis included all definitions of thrombocytopenia.
How were decisions on the relevance of primary studies made? Two reviewers independently assessed studies for inclusion and any disagreements were resolved by consensus.
Assessment of study quality
Quality was assessed using a modified version of the criteria of Nuromohamed et al. (reference given). Trials were assessed for randomisation, explicit inclusion and exclusion criteria, description of clinical characteristics, description of bleeding complications, accurate diagnosis of DVT and PE, blinding, drop-outs and routine platelet counts performed. These criteria were used to assign a score of between 0 and 9. A study was considered to be of a high
